00:41:38 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande



2024-08-09 Kvartalsrapport 2024-Q2
2024-06-13 Årsstämma 2024
2024-05-02 X-dag ordinarie utdelning BONEH 0.00 EUR
2024-02-26 Bokslutskommuniké 2023
2023-10-23 Extra Bolagsstämma 2023
2023-08-25 Kvartalsrapport 2023-Q2
2023-05-02 X-dag ordinarie utdelning BONEH 0.00 EUR
2023-04-28 Årsstämma 2023
2023-02-24 Bokslutskommuniké 2022
2022-08-25 Kvartalsrapport 2022-Q2
2022-04-29 X-dag ordinarie utdelning BONEH 0.00 EUR
2022-04-28 Årsstämma 2022
2022-03-17 Extra Bolagsstämma 2022
2022-02-24 Bokslutskommuniké 2021
2021-08-25 Kvartalsrapport 2021-Q2
2021-04-29 X-dag ordinarie utdelning BONEH 0.00 EUR
2021-04-28 Årsstämma 2021
2021-02-24 Bokslutskommuniké 2020
2020-08-31 Kvartalsrapport 2020-Q2
2020-04-06 X-dag ordinarie utdelning BONEH 0.00 EUR
2020-04-05 Årsstämma 2020
2020-03-20 Bokslutskommuniké 2019
2019-08-30 Kvartalsrapport 2019-Q2
2019-04-08 X-dag ordinarie utdelning BONEH 0.00 EUR
2019-04-05 Årsstämma 2019
2018-08-30 Kvartalsrapport 2018-Q2
2018-03-29 Årsstämma 2018


ListaFirst North Finland
BBS-Bioactive Bone Substitutes är verksamt inom medicinteknik. Bolaget designar, utvecklar och konstruerar biologiska implantat för patienter med benfel och läkningsbesvär. Bolagets lösningar vidaresäljs under varumärket Artebone och baseras på tricalciumfosfat (TCP) och benprotein, som stimulerar benläkningsprocessen. Bolaget grundades under 2003 och har sitt huvudkontor i Oulu.
2022-08-25 09:00:00

BBS-Bioactive Bone Substitutes Plc, Company Announcement, 25 August 2022 at 10.00 (CEST)

BBS approaches the CE marking of its first product

This release is a summary of BBS-Bioactive Bone Substitutes Plc’s half-yearly report January–June 2022. The entire report is attached to this stock exchange release as a pdf file. The report is also available on BBS-Bioactive Bone Substitutes Plc’s website at https://www.bbs-artebone.fi/.


  • Artebone Paste's CE marking application was submitted to the notified body on March 9, 332022
  • During the first half-year, BBS-Bioactive Bone Substitutes Plc (BBS) continued to implement the actions required for the registration of the company's first product (ARTEBONE® Paste) including ramping up production,and preparing for the start of marketing measures.
  • In May – June, the company arranged a rights issue, raising a total of approximately EUR 3.5 million in gross proceeds. Net proceeds after transaction costs related to the issue were approximately EUR 3.1 million.
  • After period-end, the company has repaid EUR 0.48 million of Business Finland's product development loans, EUR 0.2 million of Riverfort Global's financing
  • The company generated no revenue during the review period
  • The financial result in the review period was EUR -1.68 (-1.31) million
  • Cash flow from operations was EUR -1.496 (-1.365) million
  • Cash and cash equivalents on 30 June 2022 were EUR 3.390 (1.934) million

The figures in the review are rounded, so the sum of the individual figures may differ from the total presented. BBS's accounting period is a calendar year. Figures in parentheses refer to the corresponding period of the previous year, unless otherwise stated. The information in the review is unaudited.


Guidance for 2022
No revenue is expected during 2022.

Board of Directors outlook for 2022-23

The company has submitted the CE marking application for its first product (ARTEBONE® Paste) to the notified body, and the CE marking process is expected to take 8-12 months from the submission date (March 9, 2022), according to the announcement by the authorities. Thus, the company expects authorities to announce the decision on the approval of the application in 2023.

Further measures are required to ensure the sufficiency of the company's financing in order to implement the company’s plans following the expected approval of the CE marking. The company continues discussions to secure additional funding to enable the continuation of the development work as well as initiating commercial activities.


€ 10001-6/20221-6/20212021
Other operating income554560
Personnel expenses7284791 199
Depreciationa and amortization113113214
Other operational expenses6896631 144
Profit/Loss for the period -1 676-1 308-2 771
Cash flow for business operations-1 496-1365-2 520
Change in cash resources2 153-1 504-2 202
Equity ratio1), %43,442,335,0
Earnings per share2), EUR-0,24-0,20-0,42
Earnings per share, EUR, diluted-0,24-0,19-0,41
Number of shares at the end of period9 671 4596 571 5256 981 525
Average number of shares in the period7 130 9666 571 5255 668 393
Equity per share0,580,730,53
Cash and cash equivalents3 3901 9341 236
Equity5 4754 7803 634
Balance sheet total12 61811 30310 516

1)Equity ratio = Equity / (Balance sheet total – Advances received)
2)EPS = Profit(Loss) / Average number of share in the period


During the first half of 2022, BBS made positive progress towards its targets. In March, we submitted the CE marking application for our first product (ARTEBONE® Paste bone filler) to the notified body. The approval of the application will enable us to market and sell the product within the European Union.

The approval of the CE marking is the most important target for BBS, and our employees worked hard to enable submitting the application. Now this work continues as part of the application approval process, which according to the authorities' announcement will take 8-12 months from the date of submission (March 9, 2022). During the approval process, the authorities shall also certify the quality system of our production lines. Once these actions have been completed, we can enter the commercial phase.

We expect to receive the approval in 2023, after which the unique new generation bone substitute we have developed can be introduced to the market. During the approval process, we have continued to implement the actions required by the registration as well as ramped up production. To finance these activities, we arranged a rights issue in May –June, in which we raised a total of approximately EUR 3.1 million in net proceeds for the company. Almost 2,000 shareholders from Finland and Sweden took part in the offering. While the issue was not fully subscribed, considering the unfavorable capital market situation during the subscription period, I am satisfied with the end result. In December 2022 and May 2023, those who took part in the offering will have the opportunity to subscribe for additional shares with their warrants. The company plans to use these additional proceeds for marketing and launch preparations, to enable a faster transition to the commercial phase. I would like to thank all the subscribers for the trust they have shown in the company so far.

The company's financing is now secured for this year, and management can adjust the use of funds with its decisions. We are currently discussing additional funding to secure the continuation of development work and the starting of commercial operations, once the approval for the CE marking has been received.

I am proud of our team. They have solved all the challenges during our journey, despite several issues which have impacted our company’s operations and our operating environment. These have included the significant reform of the medical device regulation (MDR), the pandemic and the effects of the war in Ukraine. We have an important goal: the introduction of a new generation treatment to the market offering a safe, functional and cost-effective way to treat difficult bone fractures and ossification problems. The need for our product has only continued to increase. This goal guides and motivates all our actions during the second half-year.


The company announced after the review period on August 8, 2022, that Hanna Tölli, the chief operating officer and member of the BBS management team, will be on personal leave from August 8, 2022 to October 23, 2023. Jussi Jukka, who previously worked as BBS's production manager, was appointed as the new production manager and member of the management team from August 8, 2022.


The financial statement bulletin for 2022 will be published on March 23, 2023.

The company's previously published reports can be found on the BBS investor website at: https://www.bbs-artebone.fi/investors/financial-reports/.

BBS-Bioactive Bone Substitutes Oyj
Board of Directors

Nasdaq Helsinki